EMA accepts Deciphera’s MAA cell tumour treatment for review
The EMA has accepted the MAA of Deciphera Pharmaceuticals' vimseltinib to treat tenosynovial giant cell tumours for review.
The EMA has accepted the MAA of Deciphera Pharmaceuticals' vimseltinib to treat tenosynovial giant cell tumours for review.
What's Your Reaction?
